whatshot

LABP   $0.304  32.62% Market Open

Landos Biopharma Inc
show_chart Advanced Chart of LABP
Last Events:

2023-03-29 Trend pattern changed from нисходящий клин to расширяющийся канал.

2023-03-29 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-29 Trend pattern changed from расширяющийся канал to нисходящий клин.

2023-03-29 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-03-28 Trend pattern changed from нисходящий клин to расширяющийся канал.

2023-03-28 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-03-28 Trend pattern changed from расширяющийся канал to нисходящий клин.

2023-03-28 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

Current temperature: 5.38
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.29
Target: 2.73
High with 48% probability: 1.05
Analyst Recommendations:
Number of estimates 3
Target Price Mean 2.73
Mean unverified/preliminary 2.73 / 2.73
Target Price Low / High 0.20 / 6.00
Median / STD DEV 2.00 / 2.97
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd ActivelyBuy ActivelyBuy -
stoch Sell Sell -
ma20 - - -
ma50 Sell - -
ma100 Sell - -
Candlestick PatternMarch 13, 2023 Hammer - is a candlestick that consists of a small body near the high with a little or no upper shadow and a long lower tail. Considered to be a bullish pattern during a downtrend.
ISIN US5150691021
ceo Mr. Gregory Oakes
Website https://landosbiopharma.com
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.